Kissei Pharmaceutical Co. Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $18.81
- Today's High:
- $18.81
- Open Price:
- $18.81
- 52W Low:
- $17.71
- 52W High:
- $19.9
- Prev. Close:
- $19.9
- Volume:
- 400
Company Statistics
- Market Cap.:
- $931.34 million
- Book Value:
- 4269.936
- Revenue TTM:
- $70.52 billion
- Operating Margin TTM:
- 0.51%
- Gross Profit TTM:
- $32.38 billion
- Profit Margin:
- 17.24%
- Return on Assets TTM:
- 0.1%
- Return on Equity TTM:
- 6.15%
Company Profile
Kissei Pharmaceutical Co. Ltd had its IPO on under the ticker symbol KSPHF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Kissei Pharmaceutical Co. Ltd has a staff strength of 0 employees.
Stock update
Shares of Kissei Pharmaceutical Co. Ltd opened at $18.81 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $18.81 - $18.81, and closed at $18.81.
This is a -5.48% slip from the previous day's closing price.
A total volume of 400 shares were traded at the close of the day’s session.
In the last one week, shares of Kissei Pharmaceutical Co. Ltd have increased by +2.26%.
Kissei Pharmaceutical Co. Ltd's Key Ratios
Kissei Pharmaceutical Co. Ltd has a market cap of $931.34 million, indicating a price to book ratio of 0.583 and a price to sales ratio of 0.0132.
In the last 12-months Kissei Pharmaceutical Co. Ltd’s revenue was $70.52 billion with a gross profit of $32.38 billion and an EBITDA of $4.56 billion. The EBITDA ratio measures Kissei Pharmaceutical Co. Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kissei Pharmaceutical Co. Ltd’s operating margin was 0.51% while its return on assets stood at 0.1% with a return of equity of 6.15%.
In Q4, Kissei Pharmaceutical Co. Ltd’s quarterly earnings growth was a positive 100.1% while revenue growth was a positive 18.6%.
Kissei Pharmaceutical Co. Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 9.1756
- PEG
Its diluted EPS in the last 12-months stands at $2.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kissei Pharmaceutical Co. Ltd’s profitability.
Kissei Pharmaceutical Co. Ltd stock is trading at a EV to sales ratio of 0.0074 and a EV to EBITDA ratio of 0.0276. Its price to sales ratio in the trailing 12-months stood at 0.0132.
Kissei Pharmaceutical Co. Ltd stock pays annual dividends of $80 per share, indicating a yield of 3.23% and a payout ratio of 73.59%.
Balance sheet and cash flow metrics
- Total Assets
- $230.40 billion
- Total Liabilities
- $19.33 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 73.59%
Kissei Pharmaceutical Co. Ltd ended 2024 with $230.40 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $230.40 billion while shareholder equity stood at $195.83 billion.
Kissei Pharmaceutical Co. Ltd ended 2024 with $0 in deferred long-term liabilities, $19.33 billion in other current liabilities, in common stock, $121.71 billion in retained earnings and $0 in goodwill. Its cash balance stood at $23.71 billion and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Kissei Pharmaceutical Co. Ltd’s total current assets stands at $101.79 billion while long-term investments were $0 and short-term investments were $23.46 billion. Its net receivables were $27.13 billion compared to accounts payable of $5.57 billion and inventory worth $21.04 billion.
In 2024, Kissei Pharmaceutical Co. Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Kissei Pharmaceutical Co. Ltd paid $0.74 in dividends in 2024.
Other key metrics
- Current Trading Price
- $18.81
- 52-Week High
- $19.9
- 52-Week Low
- $17.71
- Analyst Target Price
- $
Kissei Pharmaceutical Co. Ltd stock is currently trading at $18.81 per share. It touched a 52-week high of $19.9 and a 52-week low of $19.9. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $20.24 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 2728.7% of the company’s stock are held by insiders while 2662% are held by institutions.
Frequently Asked Questions About Kissei Pharmaceutical Co. Ltd
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson’s disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.